Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.19 USD | -2.01% | +12.83% | +38.33% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 30.71M | Capitalization | 289M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -117M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.41 x |
P/E ratio 2024 * |
-2.69
x | P/E ratio 2025 * |
-3.84
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.43% |
1 day | -3.55% | ||
1 week | +14.43% | ||
Current month | +14.43% | ||
1 month | -0.17% | ||
3 months | -15.09% | ||
6 months | +61.76% | ||
Current year | +40.29% |
Managers | Title | Age | Since |
---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 63 | 10-12-31 |
Daniel Calkins
DFI | Director of Finance/CFO | 37 | 18-11-30 |
Jonathan Pachter
CTO | Chief Tech/Sci/R&D Officer | 66 | 11-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 67 | 17-05-02 |
John Johnson
BRD | Director/Board Member | 66 | 20-04-22 |
Michael Kauffman
CHM | Chairman | 60 | 12-11-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.47% | 4 M€ | -5.15% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 11.26 | -1.40% | 42 260 |
24-05-07 | 11.42 | -3.55% | 144,365 |
24-05-06 | 11.84 | +8.62% | 195,250 |
24-05-03 | 10.9 | +5.21% | 104,270 |
24-05-02 | 10.36 | +3.81% | 78,935 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.29% | 289M | |
+10.44% | 107B | |
+0.82% | 106B | |
+8.59% | 23.47B | |
-13.89% | 21.9B | |
-5.94% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- VSTM Stock